Skip to main content
. Author manuscript; available in PMC: 2019 Apr 26.
Published in final edited form as: Cancer Res. 2015 Apr 23;75(12):2510–2519. doi: 10.1158/0008-5472.CAN-14-3687

Figure 4.

Figure 4

Impact of sorafenib dose escalation. A, dose-escalating sorafenib to 60 mg/kg significantly increased drug levels in the livers (P = 0.0089; n = 11, 9) and tumors (P = 0.0387; n = 8–9) of HCC mice, but not in the livers of tumor-free mice (P = 0.161; n = 5–6). *, P < 0.05. B, escalating the dose at disease progression slowed tumor growth (n = 5 control; 21–22 sorafenib). C, sorafenib-treated mice lost weight (~10% loss day 44), which was accelerated by dose escalation and led to animal termination. D, mice maintenance on 30 mg/kg sorafenib had superior survival (median 60 days) compared with switching to 60 mg/kg (48 days, log-rank P = 0.002; n = 21–22). E, skin rash (arrowhead) worsened by week 6 after dose escalation, then tended to improve. Arrow, switch to 60 mg/kg.